Cencora raises fiscal 2026 adjusted diluted EPS outlook to at least $17.90
COR•Cencora raised its fiscal 2026 adjusted diluted EPS outlook to at least $17.90, from a previous range of $17.75 to $17.95, citing strength in U.S. Healthcare Solutions.
1. Higher earnings outlook
Cencora now expects fiscal 2026 adjusted diluted EPS of at least $17.90, compared with its prior outlook of $17.75 to $17.95. The company said the revised outlook reflects strength in its U.S. Healthcare Solutions segment.
2. Oncology network acquisition
Cencora’s planned acquisition of American Oncology Network has an enterprise value of $2.4 billion, including up to $100 million in contingent value rights. The acquisition is expected to lift adjusted diluted EPS in its second year following closing. Cencora said it will discuss fiscal 2027 expectations on its fiscal fourth-quarter 2026 earnings call on November 4, 2026.
